Related Experiment Video
Updated: May 22, 2026

08:40
An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
Published on: March 14, 2016
Solid-phase assays of receptor-binding specificity.
Mikhail N Matrosovich1, Alexandra S Gambaryan
1Institute of Virology, Philipps University, Marburg, Germany. M.Matrosovich@gmail.com
Methods in Molecular Biology (Clifton, N.J.)
|April 25, 2012
Summary
Influenza virus host specificity is determined by its binding to sialic acids. New enzyme-linked assays quantify this binding, aiding vaccine and drug development.
Area of Science:
- Virology
- Biochemistry
- Immunology
Background:
- Influenza virus infection begins with binding to sialic acid molecules on host cells.
- Differences in sialic acid receptors across species influence influenza virus host range and tropism.
- Understanding viral receptor specificity is crucial for developing effective influenza vaccines and antiviral drugs.
Purpose of the Study:
- To describe two novel solid-phase enzyme-linked receptor-binding assays.
- To enable the measurement of influenza virus binding to various sialic acid analogues.
- To provide insights into factors governing viral host range and pathogenesis.
Main Methods:
- Two enzyme-linked immunosorbent assays (ELISA)-like protocols were developed.
- Assays immobilize influenza virus and measure binding to soluble sialic acid analogues.
- Direct binding and fetuin-binding inhibition assays quantify virus-receptor interactions and association constants.
Main Results:
- The assays allow for the determination of influenza virus binding to diverse receptor analogues.
- Apparent association constants for virus-receptor complexes can be calculated.
- The fetuin-binding inhibition assay quantifies analogue competition for virus binding.
Conclusions:
- These assays offer a robust method for characterizing influenza virus receptor specificity.
- The developed protocols can aid in understanding viral adaptation and host tropism.
- This knowledge can inform the design of next-generation influenza vaccines and therapeutics.
